What are the investment strengths of Corvex Inc (MOVE)?

Pre-revenue biotech/medtech with 6.9M R&D spend could be developing valuable IP. Market cap 6.1M implies near-zero option value on pipeline. Inventory of 2.5M suggests product exists and potential for revenue ramp if commercialization succeeds.

What are the investment risks for Corvex Inc (MOVE)?

Imminent dilution risk: 2M cash / 13.6M annual burn = ~2 months runway. Any financing at 6M market cap will be massively dilutive. Negative gross margin (-270%) means every sale loses money. No path to profitability without fundamental unit economics fix.

How does Corvex Inc fit the Distressed Biotech Turnaround Screen investing approach?

Pre-revenue biotech/medtech with 6.9M R&D spend could be developing valuable IP. Market cap 6.1M implies near-zero option value on pipeline. Key filters: > 5x Total Revenue (pre-commercial R&D stage), > 12 months burn rate (runway cushion), > 0 (avoid insolvent balance sheets).

Corvex Inc

MOVE

—

Build a strategy around MOVE

Corvex Inc AI Insights

Informational only. Not investment advice.

As of 2026-01-16

Snapshot

Negative equity (-1.7M) with 7.3M liabilities vs 5.6M assets - technically insolvent. Cash of 2M covers ~2 months at -13.6M FCF burn rate.[Total Equity]
Gross margin -270% TTM (cost 1.9M on 500K revenue) - selling product below cost. Industry median +35%.[Gross Margin]
R&D of 6.9M TTM is 14x revenue (500K) - pre-commercial stage company burning cash on development.[Research and Development]

Watch Triggers

Cash and Equivalents: Falls below 1M or new financing announced — Signals imminent dilution or going concern risk
Gross Margin: Turns positive — Would indicate viable unit economics and commercialization progress
Total Revenue: Exceeds 2M quarterly — 4x current run rate would suggest product-market traction

Bull Case

Pre-revenue biotech/medtech with 6.9M R&D spend could be developing valuable IP. Market cap 6.1M implies near-zero option value on pipeline.

Research and DevelopmentMarket Cap

Inventory of 2.5M suggests product exists and potential for revenue ramp if commercialization succeeds.

InventoryTotal Revenue

Bear Case

Imminent dilution risk: 2M cash / 13.6M annual burn = ~2 months runway. Any financing at 6M market cap will be massively dilutive.

Cash and EquivalentsFree Cash FlowShares Outstanding

Negative gross margin (-270%) means every sale loses money. No path to profitability without fundamental unit economics fix.

Gross MarginGross Profit

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

15%

Leverage MOVE's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Without capital raise in next 60-90 days, company faces severe liquidity crisis or dilutive financing

3-12mhigh

2M cash vs 13.6M annual burn
Negative working capital -2.1M
No equity cushion for debt

FCF TTM -13.6MCash 2MTotal Equity -1.7M

Valuation Context

Caveats

MOVE Fundamentals

Professional, Scientific, and Technical Services → Professional, Scientific, and Technical Services

Metric	Value	Industry Percentile
Market Cap	$54.09M	—
Enterprise Value	$41.57M	—
P/E Ratio	0.00	—
Total Revenue - TTM	$737,000	—
Earnings Per Share (diluted) - TTM	$-0.27	—
Operating Margin - TTM	-2,050%	—
Net Margin - TTM	-2,458%	—
Free Cash Flow - TTM	$-17.49M	—
Return on Common Equity - TTM	-1,181%	—
Beta 5Y (Monthly)	unknown	—

MOVE Dividend History

No dividends

MOVE Stock Splits

1 stock split

04/07/261:1.358 split

MOVE SEC Filings

Filing Date	Report Date	Report Type	Filing Link
05/19/26	03/31/26	10-Q	0001213900-26-058993
03/31/26	12/31/25	10-K	0001213900-26-036609
12/22/25	09/30/25	S-4	0001213900-25-124014
09/30/25	09/30/25	S-4	0001213900-25-124014
05/19/26	03/31/25	10-Q	0001213900-26-058993